Skip to content
  • Sunday, 26 July 2026
  • 3:40 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Filspari Secures Landmark FDA Approval for Focal Segmental Glomerulosclerosis (FSGS) in Adults and Pediatric Patients Aged Eight and Above
Pharmaceutical R&D

Filspari Secures Landmark FDA Approval for Focal Segmental Glomerulosclerosis (FSGS) in Adults and Pediatric Patients Aged Eight and Above

Teuku Ryan Apr 14, 2026 0

Travere Therapeutics has achieved a significant milestone in the treatment of rare kidney diseases with the U.S. Food and Drug…

Read More
Eli Lilly’s Retatrutide Shows Unprecedented Weight Loss, But Increased Side Effects Raise Tolerability ConcernsIsomorphic Labs Secures $2.1 Billion in Series B Funding to Accelerate AI-Driven Drug Discovery and DevelopmentThe Silent Hum of Decline: How Sulfoxaflor Threatens Bumblebee Reproduction and Global Food SecurityRethinking Artificial Intelligence in Cognitive Science as New Research Challenges the Centaur Model
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ